Table 1.
Cases and/or series of PAUs stratified according to the year of publication, number of patients, age, sex, risk factors, and treatment characteristics
| Study (reference) | Number of patients | Mean age (y) | Sex (male/female) | Risk | Treatment |
|---|---|---|---|---|---|
| Lagaay [21] | 3 | 58 | 3/0 | HTN-CAD | ABI (2)-tube (1) |
| Cornud et al. [22] | 1 | 53 | 1/0 | CAD | Tube |
| Barbier et al. [23] | 1 | 73 | 0/1 | NA | ABI |
| Aschraft et al. [24] | 1 | 60 | 0/1 | HTN-PAD | Tube |
| Nora and Hollier [25] | 1 | 56 | 1/0 | HTN | Surgical interposition graft |
| Barba et al. [26] | 1 | 37 | 1/0 | NA | Surgical interposition graft |
| Rothwell and Lane [27] | 1 | 72 | 1/0 | HTN | Tube |
| Harris et al. [13] | 10 | 74 | 10/0 | HTN-CKD-CAD | Medical (3), surgical interposition graft (7) |
| Origuchi et al. [28] | 4 | 59 | 3/1 | HTN (1) | ABI (3)-tube (1) |
| Goldstein et al. [29] | 1 | 67 | 1/0 | HTN-CAD | Dacron aorto-iliac graft |
| Moriyama et al. [30] | 1 | 74 | 1/0 | HTN | Woven Dacron aorto-iliac graft |
| Taylor nd Kalman [31] | 4 | 73 | 4/0 | HTN-CAD-PAD | Tube Dacron (2)-Dacron patch (2) |
| Hayashi et al. [32] | 1 | 73 | 1/0 | NA | Medical |
| Quint et al. [33] | 1 | NA | Medical | ||
| Toda et al. [34] | 2 | 70 | 2/0 | HTN-CAD-PAD | Surgical interposition graft |
| Farooq et al. [35] | 2 | 68 | 2/0 | HTN (2)-PAD | ABI (1)-tube (1) |
| Ganaha et al. [12] | 31 | 71 | 15/16 | HTN | Interposition stent graft |
| Tsuji et al. [17] | 4 | 79.5 | 4/0 | HTN (4)-CAD (2) | EVAR (4) |
| Vasquez et al. [36] | 1 | 81 | 1/0 | HTN (1) | Stent graft |
| Saiki et al. [37] | 1 | 81 | 0/1 | HTN (1) | Resection graft (AFB) |
| Feld et al. [38] | 1 | 68 | 1/0 | CKD | EVAR (1) |
| Minor et al. [39] | 2 | 55 | 2/0 | HTN-CAD-PAD | ABI (2) |
| Ventura et al. [40] | 1 | 68 | 0/1 | HTN (1) | ABI |
| Takagi et al. [41] | 1 | 64 | 1/0 | NA | Surgical interposition graft |
| Batt et al. [18] | 8 | 70 | 7/1 | HTN (4)-CAD (3)-PAD (6) | Surgical interposition graft (5) (tube 3-Dacron aorto-iliac graft 2)- EVAR (3) |
| Chernenkov et al. [42] | 1 | 80 | 1/0 | HTN | Tube |
| Tanigushi et al. [43] | 1 | 82 | 0/1 | CAD | Hemashield tube, left aortorenal bypass |
| Sensi et al. [44] | 11 | 76.7 | 10/1 | HTN (9)-CKD (1)-CAD (6) | ABI (4)-tube (1)- EVAR (6) |
| Eggebrecht et al. [45] | 22 | 69.1 | 16/6 | HTN (2)-CKD (9)-CAD (12) | EVAR (22) |
| Thalheimer et al. [46] | 1 | 57 | 1/0 | HTN-CAD-PAD | Tube (1) |
| Dalainas et al. [47] | 2 | 68.6 | 2/0 | HTN (2)-CKD (2)-CAD (5) | EVAR (2) |
| Piffaretti et al. [48] | 13 | 73 | 12/1 | HTN (13)-CKD (2)-CAD (2)-PAD (6) | EVAR (13) |
| Fyntanidou et al. [49] | 4 | 67 | 4/0 | HTN (4)-CKD (1)-CAD (1) | EVAR (4) |
| Lindblad et al. [50] | 19 | 72 | 16/3 | NA | EVAR (19) |
| Afifi et al. [51] | 1 | 76 | 0/1 | HTN-CAD-PAD | EVAR (1) |
| Hyhlik-Dürr et al. [52] | 20 | 72 | 20/0 | HTN (19)-CKD (4)-CAD (8) | EVAR (20) |
| Kutsukata et al. [53] | 1 | 64 | 0/1 | HTN | Dacron aorto-iliac graft (1) |
| Ferro et al. [54] | 1 | 64 | 0/1 | HTN-CAD | EVAR (1) |
| Kainuma et al. [55] | 1 | 67 | 1/0 | HTN | EVAR (1) |
| Nathan et al. [56] | 20 | NA | EVAR (10)-open repair (10) | ||
| Sadeghi-Azandaryani et al. [57] | 1 | 76 | 1/0 | HTN-CAD | EVAR (1) |
| Kazan et al. [58] | 3 | 71 | 2/1 | HTN (1)-CAD | EVAR (3) |
| Palombo et al. [59] | 3 | 67 | 3/0 | HTN (3)-CKD (2)-CAD (4)-PAD (2) | EVAR (3) |
| Papazoglou et al. [60] | 1 | 69 | 1/0 | HTN | EVAR |
| Georgiadis et al. [61] | 19 | 70 | 18/1 | HTN (18)-CKD (8)-CAD (11)-PAD (9) | EVAR (19) |
| Total | 230 | 49/164 (29.9%)a | 115/164 (70.1%)b |
PAUs, penetrating atherosclerotic ulcers; HTN, hypertension; CAD, coronary artery disease; ABI, aortoiliac graft; NA, not available; PAD, peripheral arterial disease; CKD, chronic kidney disease; EVAR, endovascular aneurysm repair; AFB, axillary bifemoral bypass; IMH, intramural hematoma; SA, saccular aneurysm.
a
Surgical treatment,
b
endovascular repair.